您的购物车当前为空
别名 (R)-卢瑞色替, (R)-RP-6306, (R)-RP6306
(R)-Lunresertib 是 PKMYT1 抑制剂 RP-6306 的对映异构体,可通过磷酸化 CDK1 的苏氨酸14位点并促进其胞质滞留实现负向调控。(R)-Lunresertib 在 CCNE1 扩增的异种移植瘤模型中表现出单药抗肿瘤活性,并与吉西他滨联用时在 CCNE1 扩增或过表达的细胞系中产生协同效应,是癌症药理学及精准肿瘤学研究中的关键工具化合物。

(R)-Lunresertib 是 PKMYT1 抑制剂 RP-6306 的对映异构体,可通过磷酸化 CDK1 的苏氨酸14位点并促进其胞质滞留实现负向调控。(R)-Lunresertib 在 CCNE1 扩增的异种移植瘤模型中表现出单药抗肿瘤活性,并与吉西他滨联用时在 CCNE1 扩增或过表达的细胞系中产生协同效应,是癌症药理学及精准肿瘤学研究中的关键工具化合物。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 328 | 6-8周 | |
| 5 mg | ¥ 993 | 6-8周 | |
| 10 mg | ¥ 1,860 | 6-8周 | |
| 25 mg | ¥ 4,130 | 6-8周 | |
| 50 mg | ¥ 5,880 | 6-8周 | |
| 100 mg | ¥ 7,950 | 6-8周 | |
| 200 mg | ¥ 10,700 | 6-8周 | |
| 1 mL x 10 mM (in DMSO) | ¥ 693 | 6-8周 |
(R)-Lunresertib 相关产品
| 产品描述 | (R)-Lunresertib is the enantiomer of the PKMYT1 inhibitor RP-6306, which negatively regulates CDK1 via phosphorylation of threonine 14 and cytoplasmic sequestration. (R)-Lunresertib demonstrates single-agent antitumor efficacy in CCNE1-amplified xenograft models and shows synergistic effects with gemcitabine in CCNE1-amplified or overexpressing cell lines, providing a critical tool in cancer pharmacology and precision oncology research. |
| 靶点活性 | PKMYT1:1360 nM |
| 别名 | (R)-卢瑞色替, (R)-RP-6306, (R)-RP6306 |
| 分子量 | 324.38 |
| 分子式 | C18H20N4O2 |
| CAS No. | 2719793-91-4 |
| 颜色 | Yellow |
| 物理性状 | Solid |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 80 mg/mL (246.62 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容